Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques

被引:240
作者
Hazuda, DJ
Young, SD
Guare, JP
Anthony, NJ
Gomez, RP
Wai, JS
Vacca, JP
Handt, L
Motzel, SL
Klein, HJ
Dornadula, G
Danovich, RM
Witmer, MV
Wilson, KAA
Tussey, L
Schleif, WA
Gabryelski, LS
Jin, LX
Miller, MD
Casimiro, DR
Emini, EA
Shiver, JW
机构
[1] Merck Res Labs, Dept Biol Chem, W Point, PA 19486 USA
[2] Merck Res Labs, Dept Med Chem, W Point, PA 19486 USA
[3] Merck Res Labs, Dept Lab Anim Res, W Point, PA 19486 USA
[4] Merck Res Labs, Dept Vaccine Res, W Point, PA 19486 USA
[5] Merck Res Labs, Dept Drug Metab & Pharmaceut Res, W Point, PA 19486 USA
关键词
D O I
10.1126/science.1098632
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
We describe the efficacy of L-870812, an inhibitor of HIV-1 and SIV integrase, in rhesus macaques infected with the simian-human immunodeficiency virus (SHIV) 89.6P. When initiated before CD4 cell depletion, L-870812 therapy mediated a sustained suppression of viremia, preserving CD4 levels and permitting the induction of virus-specific cellular immunity. L-870812 was also active in chronic infection; however, the magnitude and durability of the effect varied in conjunction with the pretreatment immune response and viral load. These studies demonstrate integrase inhibitor activity in vivo and suggest that cellular immunity facilitates chemotherapeutic efficacy in retroviral infections.
引用
收藏
页码:528 / 532
页数:5
相关论文
共 19 条
  • [1] ANTHONY NJ, 2002, Patent No. [0230931, 00230931]
  • [2] HIV-1 integrase: Structural organization, conformational changes, and catalysis
    Asante-Appiah, E
    Skalka, AM
    [J]. ADVANCES IN VIRUS RESEARCH, VOL 52, 1999, 52 : 351 - 369
  • [3] Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy
    Chaisson, RE
    Keruly, JC
    Moore, RD
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (24): : 3128 - 3129
  • [4] Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies
    Egger, M
    May, M
    Chêne, G
    Phillips, AN
    Ledergerber, B
    Dabis, F
    Costagliola, D
    Monforte, AD
    de Wolf, F
    Reiss, P
    Lundgren, JD
    Justice, AC
    Staszewski, S
    Leport, C
    Hogg, RS
    Sabin, CA
    Gill, MJ
    Salzberger, B
    Sterne, JAC
    [J]. LANCET, 2002, 360 (9327) : 119 - 129
  • [5] HIV integrase structure and function
    Esposito, D
    Craigie, R
    [J]. ADVANCES IN VIRUS RESEARCH, VOL 52, 1999, 52 : 319 - 333
  • [6] Development of resistance against Diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations
    Fikkert, V
    Van Maele, B
    Vercammen, J
    Hantson, A
    Van Remoortel, B
    Michiels, M
    Gurnari, C
    Pannecouque, C
    De Maeyer, M
    Engelborghs, Y
    De Clercq, E
    Debyser, Z
    Witvrouw, M
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (21) : 11459 - 11470
  • [7] Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
    Furtado, MR
    Callaway, DS
    Phair, JP
    Kunstman, KJ
    Stanton, JL
    Macken, CA
    Perelson, AS
    Wolinsky, SM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (21) : 1614 - 1622
  • [8] HASUDA DJ, UNPUB
  • [9] Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
    Hazuda, DJ
    Felock, P
    Witmer, M
    Wolfe, A
    Stillmock, K
    Grobler, JA
    Espeseth, A
    Gabryelski, L
    Schleif, W
    Blau, C
    Miller, MD
    [J]. SCIENCE, 2000, 287 (5453) : 646 - 650
  • [10] Real time quantitative PCR
    Heid, CA
    Stevens, J
    Livak, KJ
    Williams, PM
    [J]. GENOME RESEARCH, 1996, 6 (10): : 986 - 994